A detailed history of Ubs Asset Management Americas Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 90,349 shares of EYPT stock, worth $584,558. This represents 0.0% of its overall portfolio holdings.

Number of Shares
90,349
Previous 68,630 31.65%
Holding current value
$584,558
Previous $548,000 22.81%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$7.02 - $12.12 $152,467 - $263,234
21,719 Added 31.65%
90,349 $673,000
Q3 2024

Nov 14, 2024

SELL
$7.58 - $10.54 $80,469 - $111,892
-10,616 Reduced 13.4%
68,630 $548,000
Q2 2024

Aug 13, 2024

BUY
$8.16 - $22.89 $564,231 - $1.58 Million
69,146 Added 684.61%
79,246 $689,000
Q1 2024

May 15, 2024

BUY
$19.93 - $29.71 $201,293 - $300,071
10,100 New
10,100 $208,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $220M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.